These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 28606923)

  • 1. Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells.
    Jiang BY; Li YS; Guo WB; Zhang XC; Chen ZH; Su J; Zhong WZ; Yang XN; Yang JJ; Shao Y; Huang B; Liu YH; Zhou Q; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Wu SY; Gao CY; Zhang X; Wu YL
    Clin Cancer Res; 2017 Sep; 23(18):5480-5488. PubMed ID: 28606923
    [No Abstract]   [Full Text] [Related]  

  • 2. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
    Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
    Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
    Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
    Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.
    Zheng MM; Li YS; Jiang BY; Tu HY; Tang WF; Yang JJ; Zhang XC; Ye JY; Yan HH; Su J; Zhou Q; Zhong WZ; Yang XN; Guo WB; Chuai S; Zhang Z; Chen HJ; Wang Z; Liu C; Wu YL
    J Thorac Oncol; 2019 May; 14(5):924-932. PubMed ID: 30659989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
    Zhao J; Ye X; Xu Y; Chen M; Zhong W; Sun Y; Yang Z; Zhu G; Gu Y; Wang M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1305-1310. PubMed ID: 27770237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
    Sakata Y; Kawamura K; Shingu N; Ichikado K
    Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
    Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
    Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer.
    Cho JH; Sim MH; Kim SY; Kim K; Lee T; Lee J; Kang WK; Kim ST
    J Cancer Res Ther; 2021; 17(4):1047-1051. PubMed ID: 34528562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
    Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
    Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].
    Li H; Xie Y; Lin Y; Yu T; Yin Z
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):646-654. PubMed ID: 32838487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer.
    Fan Y; Zhu X; Xu Y; Lu X; Xu Y; Wang M; Xu H; Ding J; Ye X; Fang L; Huang Z; Gong L; Lu H; Mao W; Hu M
    Clin Cancer Res; 2018 Jan; 24(1):209-216. PubMed ID: 29030356
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
    He J; Tan W; Ma J
    Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptomeningeal metastases in non-small-cell lung cancer.
    Cheng H; Perez-Soler R
    Lancet Oncol; 2018 Jan; 19(1):e43-e55. PubMed ID: 29304362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
    Berger LA; Janning M; Velthaus JL; Ben-Batalla I; Schatz S; Falk M; Iglauer P; Simon R; Cao R; Forcato C; Manaresi N; Bramlett K; Buson G; Hanssen A; Tiemann M; Sauter G; Bokemeyer C; Riethdorf S; Reck M; Pantel K; Wikman H; Loges S
    J Thorac Oncol; 2018 Dec; 13(12):e243-e246. PubMed ID: 30205165
    [No Abstract]   [Full Text] [Related]  

  • 20. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.